Hearing loss class labeling for ED drugs
Executive Summary
FDA is updating labeling for phosphodiesterase type 5 inhibitors to highlight the risk of sudden hearing loss, though the agency is not asserting a causal link. The drug class includes the erectile dysfunction drugs Cialis, Levitra and Viagra and the pulmonary arterial hypertension treatment Revatio (sildenafil citrate). Viagra (sildenafil citrate) labeling previously listed "deafness" and "tinnitus" in the Adverse Reactions section, but Levitra (vardenafil) and Cialis (tadalafil) labeling did not include those risks. Now labeling will be consistent across the PDE-5 inhibitor class, including the addition of information about hearing loss in the Precautions section. FDA identified 29 postmarketing reports of sudden hearing loss in its Adverse Events Reporting System, the agency says Oct. 19...
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.